help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Karmazyn, M.
Right arrow Articles by Horrobin, D. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Karmazyn, M.
Right arrow Articles by Horrobin, D. F.

Endocrinology, Vol 102, 1230-1236, Copyright © 1978 by Endocrine Society

ARTICLES

Changes of vascular reactivity induced by low vasopressin concentrations: interactions with cortisol and lithium and possible involvement of prostaglandins

M Karmazyn, MS Manku and DF Horrobin

Arginine vasopressin in physiological concentrations potentiated the vascular effects of various vasoconstrictor agents. By using the isolated rat mesenteric artery preparation, the pressor effects of norepinephrine, angiotensin II, and potassium chloride were all significantly increased when vasopressin was added to the perfusion buffer. Cortisol and lithium both inhibited the potentiating effect of vasopressin but had no effect on the control pressor response to norepinephrine. When the vascular effects of norepinephrine were first blocked with indomethacin and then restored by the addition of prostaglandin E2, the potentiation by vasopressin was almost completely prevented. This suggests that vasopressin may be acting by stimulating prostaglandin biosynthesis. Cortisol and lithium may exert their inhibitory effects by preventing the activation of prostaglandin synthesis by vasopressin. These findings may be of clinical significance because the phenomena occur well within the range of vasopressin levels found in human plasma.


This article has been cited by other articles:


Home page
 ChestHome page
C. L. Holmes, B. M. Patel, J. A. Russell, and K. R. Walley
Physiology of Vasopressin Relevant to Management of Septic Shock
Chest, September 1, 2001; 120(3): 989 - 1002.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
G. Segarra, P. Medina, C. Domenech, J. M. Vila, J. B. Martínez-León, M. Aldasoro, and S. Lluch
Role of Vasopressin on Adrenergic Neurotransmission in Human Penile Blood Vessels
J. Pharmacol. Exp. Ther., September 1, 1998; 286(3): 1315 - 1320.
[Abstract] [Full Text]

Home page
 CirculationHome page
P. Medina, A. Acuna, J. B. Martinez-Leon, E. Otero, J. M. Vila, M. Aldasoro, and S. Lluch
Arginine Vasopressin Enhances Sympathetic Constriction Through the V1 Vasopressin Receptor in Human Saphenous Vein
Circulation, March 10, 1998; 97(9): 865 - 870.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1978 by The Endocrine Society